Kapiva Unleashes a New Era of Ayurveda with a Power-Packed $60 Million Investment

In a resounding vote of confidence for traditional wellness modernized for the 21st century, Kapiva, the pioneering direct-to-consumer (D2C) brand at the forefront of Ayurvedic health, has successfully closed a robust $60 million Series B funding round. This substantial investment is set to supercharge the brand's ambitious plans for extensive research and development, aggressive brand building, innovative product diversification, and a significant expansion into new markets, both domestically and across the globe.

The funding round saw leadership from prominent investors 360 ONE Asset (formerly known as IIFL Asset Management) and Vertex Ventures Southeast Asia & India.

Their involvement underscores the growing investor appetite for disruptive D2C brands that tap into India's rich heritage while leveraging modern scientific validation and digital reach. Existing investors, including Fireside Ventures and unlisted public market investors, also participated, further cementing their belief in Kapiva's vision and growth trajectory.

Founded in 2016 by the visionary duo Ameve Sharma and Shrey Badhani, Kapiva embarked on a mission to demystify and democratize Ayurveda, making its profound benefits accessible and relevant to contemporary consumers.

Their approach bridges ancient wisdom with modern science, focusing on creating clinically-proven, high-quality Ayurvedic products that address a spectrum of health needs.

This fresh infusion of capital arrives at a pivotal moment for Kapiva. The company plans to allocate a significant portion towards accelerating its R&D capabilities, a core pillar of its strategy.

This will enable the development of groundbreaking Ayurvedic formulations, ensuring each product is backed by rigorous scientific research and efficacy. Furthermore, the brand will intensify its marketing and brand-building efforts, aiming to solidify its position as a trusted household name in health and wellness.

Product development will also see a substantial boost, allowing Kapiva to expand its already diverse portfolio of over 100 products, which spans crucial categories like digestive health, weight management, and sexual wellness.

The brand is dedicated to continuously innovating and introducing solutions that cater to the evolving health conscious consumer.

Perhaps one of the most exciting outcomes of this funding is Kapiva’s strategic push into new markets. While it has established a strong online presence, the brand is now poised to make significant inroads into offline channels across India, ensuring wider accessibility.

Globally, the United States market is a key target, signifying Kapiva's ambition to transform from a leading Indian D2C brand into a recognized international player in the natural health space.

Kapiva's growth has been nothing short of remarkable, reportedly achieving an annual recurring revenue (ARR) of Rs 250 crore.

This impressive financial performance is a testament to its successful direct-to-consumer model and its ability to resonate with a health-aware audience seeking authentic, effective, and convenient Ayurvedic solutions. The brand's emphasis on scientific validation, transparent ingredient sourcing, and a holistic approach to well-being has clearly struck a chord.

With this substantial capital injection, Kapiva is well-positioned to cement its leadership in the D2C Ayurveda segment, expand its global footprint, and continue its mission of bringing the timeless wisdom of Ayurveda to a modern, health-conscious world.

The future looks incredibly bright for this innovative brand as it sets out to redefine wellness on a global scale.